Mezdutide

Mazdutide (IBI362) is described as a long-acting dual GLP-1 / glucagon receptor agonist studied for chronic weight management and type 2 diabetes. The source describes a once-weekly subcutaneous protocol with gradual titration to improve tolerability. (Educational context only.)

Dosing Schedule (Standard / Gradual Titration — 3.0 mL → ~3.33 mg/mL):
Route & Frequency: Inject once weekly via the subcutaneous route. Aim for the same day each week and rotate sites.

Easy Measuring: At ~3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.3 mcg on a U-100 insulin syringe.

Advanced / High-Dose Protocol (2.0 mL → 5.0 mg/mL):
The source includes higher-dose weekly schedules (explored in early research) and notes a higher risk of GI side effects at higher doses. Educational context only.

High-Volume Tip: If a planned dose would require more than ~3.0 mL total volume, split into two injections at different sites.

Reconstitution Instructions (Standard):
• Draw 3.0 mL bacteriostatic water using a sterile syringe (yields ~3.33 mg/mL).
• Inject slowly along the vial wall to minimize foaming.
• Gently swirl/roll until fully dissolved (do not shake vigorously).
• Label with the date and refrigerate at 2–8 °C, protected from light.

Storage Notes (As Listed):
• Lyophilized: store frozen at −20 °C (−4 °F).
• Reconstituted: refrigerate at 2–8 °C (35.6–46.4 °F).
• Avoid freeze–thaw cycles; do not freeze reconstituted solution.
• Discard after 28 days or if cloudiness/particulates appear.

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Sequence: GLP-1/Glucagon receptor dual agonist

Molecular Formula: C₁₇₉H₂₈₈N₅₀O₅₂

Molecular Weight: 3998.57 g/mol

Synonyms: OXM3, IBI362

Preclinical studies on Mezdutide have demonstrated its potential to significantly reduce body weight and improve metabolic health. Animal models have shown that Mezdutide can effectively regulate appetite, enhance energy expenditure, and improve insulin sensitivity, providing a solid foundation for its therapeutic use.

Mezdutide is currently undergoing clinical trials to further evaluate its safety and efficacy in humans. Initial results from these trials have been promising, with participants experiencing notable weight loss and improved glycemic control. These findings support the potential of Mezdutide as a novel treatment option for obesity and type 2 diabetes.

The future of Mezdutide in metabolic health is bright. As research continues to validate its effectiveness and safety, Mezdutide is expected to become a key player in the management of obesity and type 2 diabetes. Its ability to target specific metabolic pathways offers a new and promising approach to treating these conditions, potentially leading to better patient outcomes.

The development of Mezdutide represents a significant advancement in peptide-based therapies. Its unique mechanism of action and therapeutic benefits highlight the potential of peptides in addressing complex metabolic disorders. Ongoing research and development may lead to the discovery of additional peptides with similar or enhanced properties, further expanding the possibilities in this field.

The ultimate goal of Mezdutide's development is to improve the quality of life for individuals affected by metabolic disorders. By providing a targeted and effective treatment option, Mezdutide has the potential to help patients achieve better health outcomes, reduce the burden of chronic diseases, and enhance overall well-being.

Mezdutide's potential to significantly improve metabolic health and manage weight makes it a crucial development in medical research. It offers new approaches to treating obesity and metabolic disorders such as type 2 diabetes.

PubMed

The above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from https://case.edu/medicine/Case Western Reserve University School of Medicine and a B.S. in molecular biology.

Case Western Reserve University School of Medicine

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.

The product information featured on this website pertains exclusively to in-vitro studies. In-vitro studies, also known as 'in glass' studies, are conducted outside of living organisms. It's important to emphasize that these products do not constitute medicines or drugs and have not received FDA approval for the prevention, treatment, or cure of any medical conditions, ailments, or diseases. It is crucial to note that the introduction of these products into the bodies of humans or animals is strictly prohibited by law.